Excelra Releases COVID-19 Drug Repurposing Database to Support Global Drug Development Efforts Against Novel Coronavirus
PR83631
HYDERABAD, India, April 9, 2020 /PRNewswire=KYODO JBN/ --
Excelra, a leading global data and analytics company, today announced the
release of the COVID-19 Drug Repurposing Database
(https://www.excelra.com/covid-19-drug-repurposing-database/). The
'open-access' database presents a compilation of 'previously approved' small
molecules and biologics with known preclinical, pharmacokinetic,
pharmacodynamic, and toxicity profiles that can rapidly enter either Phase 2 or
3 clinical trials on fast track basis for COVID-19. In addition, the database
also includes information on promising drug candidates that are in various
'clinical, pre-clinical and experimental' stages of drug discovery and
development for COVID-19.
Alluding to this wealth of information, Dr. Nandu Gattu, Senior Vice
President, Pharma Analytics, Excelra said, "The COVID-19 DR database is a
compilation of crucial data that is dispersed across numerous publications,
reports, databases and knowledge-repositories along with referenced literature
covering the drug, disease, target, and mechanism of action. Our endeavour is
in support to the ongoing global scientific efforts for identifying safe and
effective therapeutic options to treat the novel coronavirus disease."
Drug Repurposing at Excelra is powered by their Global Repurposing
Integrated Platform (GRIP) that combines proprietary repurposing databases,
algorithms, analytics tools and a visualization engine. The GRIP database is
built by amassing vast chemical data, biological data and clinical data which
together contribute to more than 10 million associations among
'drug-disease-target' triads.
https://www.excelra.com/translational/#drug_repositioning
About Excelra:
Excelra's data and analytics solutions empower innovation in life sciences
across the value chain from discovery to market. The Excelra Edge comes from a
seamless amalgamation of proprietary curated data assets, deep domain expertise
and data science. The company's multifaceted teams harmonize and analyse large
volumes of disparate unstructured data using cutting-edge technologies. We
galvanize data-driven decisions to unlock operational efficiencies to
accelerate drug discovery and development. Over the past 18 years, Excelra has
been the preferred data and analytics partner to over 150 global clients
including 15 of the top 20 large Pharma companies.
www.excelra.com
Access COVID-19 Drug Repurposing Database:
https://www.excelra.com/covid-19-drug-repurposing-database/
Contact Information:
Dorothy Paul – Director Marketing
Tel: +91-9908130236
Email: dorothy.paul@excelra.com
Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg
Source: Excelra Knowledge Solutions Pvt Ltd
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。